The name “Tortaden” comes from the Spanish word “Torta” which translates to “Cake”. This pungent and sour hybrid strain is back! This batch of Tortaden has 32.45% THC and 1.20% terpenes. Tortaden is known to have very dense buds with amber hairs and glistening trichomes. The purplish leaves on this strain reflect some of its lineages as we describe below. This is only the second time we have grown this strain but we might put this one in the starting rotation!

Lineage:

This strain was created here at CTPharma by our expert cultivation team. After careful selection and deliberation, we determined that these two strains might play nice together and create powerful offspring. We crossed our high-powered Sativa strain, Tetraden, with our popular fan-favorite hybrid, Auralex to create this dank, sticky new strain for the CTMMP.

Tetraden: This strain is extremely pungent, so it’s best stored in tightly sealed containers. The pungent aroma of Sour Kush has a sweetly citrus scent akin to lemon and lime. The taste is a spicy citrus, some even claiming there are hints of garlic, with an expected aftertaste of diesel. The dense, pine cone-shaped nuggets feature dark green leaves with shades of deep purple, covered generously with cloudy, amber trichomes and strong orange hairs. Independent testing labs have reported flowers of this strain to have between 29 and 32% THC since we have been growing this.

Auralex: This strain leans on some very popular genetics to yield a balanced high and a dynamic taste. It gives an exceptionally sweet aromatic essence and a fruity flavor. The taste is a perfect combination of the sweetness of cookies and the fruitiness of a cherry pie. In terms of looks, it is quite frosty and has dark green leaves. Independent testing labs have reported flowers of this strain to have between 27 and a staggering 34% THC over the years.

Terpenes:

β-myrcene - 0.31, limonene - 0.30, linalool - 0.31, β-caryophyllene - 0.28 TOTAL TERPENES: 1.20%

Please visit the CT MMP page for more information.

For Adults, Debilitating Medical Conditions Include:

• Cancer (Effective 2012)

• Glaucoma (Effective 2012)

• Positive Status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome (Effective 2012)

• Parkinson's Disease (Effective 2012)

• Multiple Sclerosis (Effective 2012)

• Damage to the Nervous Tissue of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)

• Epilepsy (Effective 2012)

• Cachexia (Effective 2012)

• Wasting Syndrome (Effective 2012)

• Crohn's Disease (Effective 2012)

• Post-Traumatic Stress Disorder (Effective 2012)

• Sickle Cell Disease (Effective 2016)*

• Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)*

• Severe Psoriasis and Psoriatic Arthritis (Effective 2016)*

• Amyotrophic Lateral Sclerosis (Effective 2016)*

• Ulcerative Colitis (Effective 2016)*

• Complex Regional Pain Syndrome, Type 1 and Type II (Effective 2016)*

• Cerebral Palsy (Effective 2016)

• Cystic Fibrosis (Effective 2016)

• Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)

• Terminal Illness Requiring End-Of-Life Care (Effective 2016)

• Uncontrolled Intractable Seizure Disorder (Effective 2016)

• Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)*

• Severe Rheumatoid Arthritis (Effective 2018)*

• Post Herpetic Neuralgia (Effective 2018)*

• Hydrocephalus with Intractable Headache (Effective 2018)*

• Intractable Headache Syndromes (Effective 2018)*

• Neuropathic Facial Pain (Effective 2018)*

• Muscular Dystrophy (Effective 2018)*

• Osteogenesis Imperfecta (Effective 2018)*

• Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)*

• Interstitial Cystitis (Effective 2019)*

• MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)*

• Vulvodynia and Vulvar Burning (Effective 2019)*

• Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*

• Tourette Syndrome (Effective 2019)*

• Chronic Pain of at least 6 months duration associated with a specified underlying chronic condition refractory to other treatment intervention (Effective 2020)*

• Ehlers-Danlos Syndrome Associated with Chronic Pain (Effective 2020)*
  

For Patients Under 18, Debilitating Medical Conditions Include:

• Cerebral Palsy (Effective 2016)

• Cystic Fibrosis (Effective 2016)

• Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)

• Severe Epilepsy (Effective 2016)

• Terminal Illness Requiring End-Of-Life Care (Effective 2016)

• Uncontrolled Intractable Seizure Disorder (Effective 2016)

• Muscular Dystrophy (Effective 2018)*

• Osteogenesis Imperfecta (Effective 2018)*

• Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*

• Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)*

* Conditions were approved by the Regulation Review Committee via the recommendation of the Board of Physicians and Commissioner of Consumer Protection.

Qualifications for a Registration Certificate:

• Qualifying patient must be a Connecticut resident.

• Qualifying patient cannot be an inmate confined in a correctional institution or facility under the supervision of the Connecticut Department of Corrections.

The year 2020 will be one to remember as a tough year for so many different reasons. For us, it was an even harder year as we lost our beloved co-founder and CEO, Tom Schultz. Our new t-shirt design honors our late CEO’s legacy. Beyond all the good he did in the CT MMJ program, Tom Schultz spent his younger days in Kenya (Africa) where he was a teacher in a high school in Nairobi. He spent three years there and summited Mount Kenya for the first time in 1972. He made it a regular thing to travel back frequently to climb it time and again over the years. Our t-shirts also include a tribute to these accomplishments - on the mountain, you will see a small flag bearing Tom’s initials - TS. We hope you will wear yours with pride as we, the team at CTPharma, do everyday.

---

One of our hottest topicals is back in action, the Mend T100C100 I Cooling Body Balm 10784!

Mend Balm is a cooling cannabinoid infused body balm made for topical use. The cool sensation will be refreshing anywhere you need it! Hands, heels, joints, back, etc., this smooth and creamy 1:1 balm will make your skin sing with joy.

---

---

CTPharma offers a variety of methods for patients to medicate. Here is an explanation of our products, how they work, and how to use them.

*Disclaimer: Product packaging subject to change. Not all products represented.*

---

Concentrates

Live Concentrates

Oils

Tablets

Drops, Tinctures & Sprays

Topicals

MEDICAL MARIJUANA PRODUCER CTPHARMA WILL RELOCATE FROM PORTLAND CT, TO ROCKY HILL CT

Move into 216,000 Square Foot Former McKesson Pharmaceutical Building Will Give CTPharma Largest Medical Marijuana Production Facility in Connecticut

CTPharma, a Portland, Connecticut-based medical marijuana producer licensed by the State Department of Consumer Protection today announced that a wholly-owned affiliate of CTPharma -- CTPharma Real Estate Inc. -- has purchased a  216,532 square foot building in Rocky Hill from the pharmaceutical company McKesson Corporation, which had moved out.

CTPharma CEO Tom Schultz said the company is reluctantly leaving Portland, where it enjoyed operating since the beginning of its operations in 2014 and where it has operated ever since.

“CTPharma’s relationship with the Town of Portland was excellent and we were reluctant to leave,” Schultz said. “However, there were no buildings available in Portland that were big enough for CTPharma’s planned expansion and we were very fortunate to identify and purchase the McKesson property.”

CTPharma made an application to the Rocky Hill Planning and Zoning Commission last summer and received a special permit to operate a medical marijuana production facility at the 280 Dividend Road, Rocky Hill site of the McKesson building.

CTPharma currently employs approximately 50 people in its highly regulated pharmaceutical production operations.  CTPharma currently has a groundbreaking FDA-approved clinical study underway with Yale School of Medicine as well as other current studies at Yale School of Medicine and at UCONN School of Agriculture. 

Schultz said that CTPharma expects to double its work force as it moves its operations to Rocky Hill and to steadily increase employment as it utilizes more and more of its new home.

CTPharma Chief Operating Officer Rino Ferrarese said of the move to the new facility that he looks forward to “developing CTPharma products into standard medications that the American market understands and trusts.” 

“Connecticut patients should expect quality and consistency from our products, just as they would from any other product offered on an American shelf,” Ferrarese said.

Tom Schultz, CTPharma said Connecticut’s medical marijuana program -- the leading program in the nation – has great potential to establish the foundation of a biotech industry. 

“The biotech opportunity will fall to the state whose program and products best serve the needs of its patients and we believe that CTPharma will help Connecticut be that state,” Schultz said. “We are working with a plant that obviously interacts with human biology and we have been fortunate that the legislature and the Department of Consumer Protection have given us the green light to investigate the scientific and medical potential of cannabis.”

“Unlocking that potential is the goal of the Yale/CTPharma clinical study with human subjects, and we intend to press forward with other studies that always should have been undertaken,” Schultz said.

CTPharma expects to move into the Rocky Hill facility and begin production over the next eighteen months.

During 2015, CTPharma began research efforts at the Yale School of Medicine. CTPharma now has 3 studies with Yale, one of which is a “groundbreaking” Food and Drug Administration (FDA)-approved clinical studies to study stress and pain relief in human patients.

YALE SCHOOL OF MEDICINE AND CTPHARMA ANNOUNCE GROUNDBREAKING CLINICAL STUDY WITH CANNABINOID MEDICINES.

Investigational New Drug (IND) trial will study a variety of medical conditions related to stress and pain.

Yale University School of Medicine and CTPharma will conduct a Phase One clinical study of the effectiveness of various medical marijuana formulations initially aimed at alleviating stress and pain in patients. This study is the first approved by the Department of Consumer Protection’s Medical Marijuana Research Program to study stress and mental health related issues. 

The study’s initial phase is a safety and dosing study, in this case focused on pain and stress.  The study will be the first of its type on human subjects, a double-blind, randomized, placebo-controlled clinical study using medical marijuana with an FDA-approved protocol.

The clinical study will address other conditions as appropriate based on the results of Phase One. Those conditions may include Post Traumatic Stress Disorder and opioid-replacement.

Please find our clinical trial on ClinicalTrials.gov

Learn more

CACHEXIA STUDY – YALE SCHOOL OF MEDICINE

During 2015, CTPharma began research efforts at the Yale School of Medicine.   This first study concerns cachexia, the wasting syndrome that often accompanies serious illness.  If we can understand the mechanism through which the body begins to reject nutrition, perhaps we can reverse the condition and improve the nutrition of those fighting serious disease.

PTSD STUDY – YALE SCHOOL OF MEDICINE

Our second study at Yale School of Medicine involves establishing the blood levels of cannabinoids necessary to control PTSD and other nerve system disorders.  The first phase of the study involves taking blood samples over several hours of patients under treatment to better understand safety and dosing specifics.  This information will be used to develop dosing formulations for future PTSD study phases.

CTPharma worked for five years to launch an FDA-approved clinical trial in partnership with Yale School of Medicine. Now that the company has the go-ahead, the real work begins.

By Brian MacIver.

Rino Ferrarese (left) and Tom Schultz (right), co-founders, CTPharma. Photos by Emily Savage Photo & Design, LLC

Standing in the Beaumont Room at the Yale School of Medicine on Nov. 8, flanked by school officials and medical researchers, the significance of what was transpiring in front of Rino Ferrarese and Tom Schultz was not lost on them. It was a moment the duo had been waiting and preparing for since they first chatted with each other about launching a medical cannabis operation in the Constitution State back in 2013.They were there that morning, in front of 40 or so members of the media, the medical community and state and regulatory officials, to announce that CTPharma, the company they co-founded, received Food and Drug Administration (FDA) approval to begin clinical trials on cannabinoid medicines in partnership with the Yale School of Medicine. The first phase of this Investigational New Drug (IND) study focuses on safety and dosing in treating symptoms related to stress and pain relief. These randomized, double-blind, placebo-controlled (RDBPC) studies now allow CTPharma to put its products through the scientific gauntlet.“Phase I of an FDA study is relatively straightforward,” Schultz explains. “You’re trying to prove some form of safety and efficacy.”From those early days in the state’s legal medical cannabis industry, CTPharma’s focus has been on obtaining this FDA approval to commence human studies. “To date, there hasn’t been an American company who’s been able to cultivate flower, harvest it, extract it, process it into a pharmaceutical dose, and get it through the FDA, approved in an IND protocol, and then into healthy human volunteers for a safety and efficacy study,” Ferrarese told Cannabis Business Times after the press conference. “That’s a triumph. Today will be a historic day in the annals of cannabis history.”Now that the company has the government go-ahead to begin its research, Schultz says it feels like “we’ve crossed the starting line.”

(Editor’s note: Tom Schultz and Rino Ferrarese are CBT columnists.)

PREPARING FOR THE RACE

As former executives in FDA-regulated industries, both Ferrarese and Schultz are well-suited to navigate this opportunity. Ferrarese has experience as a compliance officer working under the guidelines of Current Good Manufacturing Practices (CGMP) for the production of prescription, over-the-counter (OTC) and homeopathic human drug products. Schultz operated the last significant producer of witch hazel, Dickinson Brands Inc., until he and Ferrarese launched CTPharma.

The intent with launching a medical cannabis cultivation operation was never simply to cultivate: Research was at the forefront of their minds from day one. However, Schultz says, “when we were awarded a license [in 2014], there was no research authorized by the state’s cannabis statute. We [could] ship product for consumption to six dispensaries, but if Yale School of Medicine, to whom we were speaking, wanted to do research even in a test tube, [they] couldn’t do it. It was illegal, even in Connecticut, to ship [cannabis] to them.”

The duo knew early on that rules would need to be rewritten for them to get started on the work they wanted to complete. The CTPharma co-founders spent the better part of the business’s first two years working with regulators and elected officials (some of whom were present for the Nov. 8 announcement) to pass research-enabling legislation. Two-and-a-half years after obtaining their license, Ferrarese and Schultz helped create Connecticut’s Medical Marijuana Research Program.

---

ABOUT CTPHARMA

Business launched: 2013

Location: Portland, Conn.; Rocky Hill, Conn. (Q2 2020)

Canopy size: 10,000 sq. ft.; expanding to 173,000 sq. ft. in Q2 2020

Number of employees: 50

Products offered: 150 SKUs in 18 categories

---

Many of CTPharma’s employees come from a pharmaceutical background, both in OTC and prescription medications.

Under the state’s Department of Consumer Protection (DCP)’s supervision, hospitals, higher education institutions, medical cannabis producers and dispensaries can register to conduct research “intended to increase knowledge or information regarding the growth, processing, medical attributes, dosage forms, administration or use of marijuana to treat or alleviate symptoms of any medical conditions or the effects of such symptoms,” according to the DCP’s website. This program explicitly allows CTPharma to work with groups such as Yale School of Medicine on research once the study has been registered.

Another two-and-a-half years of working for federal approval and a “significant” six-figure investment brought CTPharma to the launch of its IND studies. The company is starting with two studies focused on both safety and efficacy. During the eight-week study period, participants cycle through four of six product formulations (including a placebo) in alternating weeks—one week on one formulation, one week off any formulations, then another week with a different formulation, and so on.

“Once we can prove safety, now we can get more focused on exactly what we can do with this medication,” Schultz explains.

BACK TO SCHOOL

CTPharma’s environmental control system allows it to operate in a state of control, where plant development has been standardized.

CTPharma selecting Yale School of Medicine as its research partner is a product of proximity and familiarity: Yale is in Connecticut, and Schultz is an alum. The third component that made the partnership attractive was mutually recognized expertise.

“[Yale] recognized the potential for cannabinoid research before anything was even authorized in Connecticut,” Schultz says. For example, while CTPharma was working to have research legislation enacted in 2016, CTPharma and Yale co-sponsored a symposium on cannabinoids in medicine. Looking back at the event, Schultz says, “we had honestly the cutting-edge researchers in the world speak at Yale and talk about exactly where research in cannabis was at that time.”

What Yale saw in CTPharma was the company’s “pharmaceutical production orientation,” Schultz says. Many of CTPharma’s employees come from a pharmaceutical background, both in OTC and prescription medications. A handful of others come from the supplement and food industries. He adds that “from [Yale’s] point of view, … we have the capacity to produce cannabinoid medication in the same way that a pharmaceutical company would produce it.”

A good example is the products CTPharma intends to use in its IND studies: Instead of smokable flower or dosed vape pen cartridges, the company offers formulated tablets to patients involved in its research. Dosages can vary from 10 mg THC:40 mg CBD to 30 mg THC:40 mg CBD. Tablets as a delivery mechanism for these cannabinoid medications were chosen not by haphazard choice, but by slow, deliberate study.

“We did membrane permeability studies, which were designed to determine how much the body uptakes,” Ferrarese explains. In other words, “if you provide 10 milligrams of medicine in a tablet and you swallow it, how much of that 10 milligrams is getting absorbed into the body in a way that the body can utilize it as medicine, and how much is getting discarded and passed into your system as waste?”

One of Ferrarese’s main criticisms of most cannabis studies done to date is the lack of available information about the quality and consistency of the product used. Additionally, combusting or heating cannabis will change its phytochemistry. For example, Ferrarese says, “if you heat [cannabis] … you can have terpenes volatilized, and once they’re gone, they’re gone. So you have to be very careful with the cannabis medicine.”

CTPharma spent time and resources on stability studies—research on its products and how they change over time in different conditions. Thanks to those efforts, Ferrarese says, “we know exactly what happens to our tablets if you heat them up too much, what happens if they freeze, what are the optimum storage conditions.” This work was all done “just to make sure that when the patient takes medicine, that we know what the patient can expect and we can better understand the results we’re getting,” he continues.

All of these studies and tests were conducted by CTPharma in a formulation lab and an analytical lab that Ferrarese describes as “[rivaling] any mid-level biotech company operating in America today.”

STATE OF CONTROL

Another big part of CTPharma’s pharmaceutical approach is its almost neurotic data collection. “In the FDA world, if you didn’t document it, it never happened,” Ferrarese says. That’s why one of the first significant cultivation investments was for a proprietary environmental control system (ECS), and the company hasn’t operated a day without one.

Since the cultivation operation’s launch in 2014, four sensors in every cultivation room have taken snapshots every 30 seconds; throughout the facility, temperature, humidity, CO2 levels, and lighting are all measured twice per minute.

It was the co-founders’ experience in FDA-regulated industries that told them data-tracking would be crucial to their goals of setting up clinical research studies; they both learned how important ongoing process control and the creation of reproducible products are to the FDA in its role as a consumer protection agency.

The data CTPharma had been collecting before it began its FDA application “was relevant and very interesting and important to the FDA because they wanted to see that we operated in a state of control,” Ferrarese explains. As CTPharma went through its IND study application, Ferrarese estimates that roughly a month was spent answering the agency’s data requests, with new ones coming almost daily.

FAST TAKE WITH TOM SCHULTZ, CO-FOUNDER AND CEO, CTPHARMA

Biggest challenge in launching or maintaining a cultivation operation: “Too many opinions. You want to limit the number of cooks in the kitchen, but you also face the perennial arguments that LEDs are better and you’re supposed to trim the leaves this way and that way, or that [plants should be that] height or this height. From our point of view, we should operate in a state of control. We try very hard to stop the noise and bring it down to identifying the methods that work best.”

Something people don’t realize about running a cannabis operation: “Science matters. … [And] our 10th harvest should be better than our first. You always have a hypothesis that you’re working on, and you either throw it out or change. You can never be satisfied with whatever you are doing at the time.”

What keeps you awake at night: “Unexpected developments, like problems in the [illicit] market, that somehow spill onto us. Issues like the recent vaping scare have, by and large, been quarantined to the illicit market, yet the regulated market has to deal with the fallout.”

What helps you sleep at night: “Routine documentation, performance, and consistency. When we’re hitting on all cylinders, we try something new and it works, that’s great. It feels like we’re moving forward, not backward.”

TIP: Advice for other cultivators: “It’s all about compliance. People should be a step ahead of their regulators. The regulations have a purpose, and my attitude is to not merely do what the regulation says but to focus on what the regulation means. Read the regulations, understand their intent, and put yourself in front of them so that the conventional problems that other people have, you don’t have.”

---

In addition to stability data on final products and formulations, the company documents everything in the cultivation areas. This includes “watering, taking clones, what time the lights came on and off, all the way through … how much did Blue Dream yield this year compared to when we grew it last year,” Ferrarese says.

The indoor cultivation operation is also designed to maximize control and minimize any unexpected outcomes: Peat moss and Pro-Mix make up the growing media, while a mix of different fertilizer inputs gets pumped through drip irrigation lines. In vegetation, double-ended metal halide lights are the company’s preferred choice. For flowering, double-ended HPS lights are what CTPharma feels give it the most control.

But both Ferrarese and Schultz are quick to point out that it’s not the company’s approach to cultivation that they believe sets it apart from other licensees in the state, but its overall pharmaceutical approach. They add that retained samples and stability testing are a safety precaution: if a patient comes to them complaining of poor product quality or that their medicine made them sick, CTPharma can trace the batch number and investigate what might have happened. That historical data also can be used as evidence to defend the company in case of a lawsuit.

RESEARCH POTENTIAL

Now that the company can begin its research projects, the co-founders expect to see a jump in the company’s value—and revenue. “If we are intelligent about the way that we work on research, then it dramatically enhances our value as a company,” Schultz says.

The first hurdle is the first phase of the IND study, which looks at safety and efficacy. Schultz isn’t worried about that first jump, given the anecdotal safety of cannabis in the U.S. (As the old industry saying goes, the only way cannabis will directly kill you is if a 60-pound bale of it falls on your head.)

Part of what CTPharma is studying in this first phase are stress and pain. Depending on the results, stress studies could transition into PTSD in phase two, and the pain research could be refocused on opioid replacement. “In any case, we see the possibility in phase two to begin to address specific problems, let’s say, for which the solutions could have very substantial economic value—and … human value,” Schultz says.

The real risk, Schultz believes, is in doing the actual research with “no guarantee that some bureaucrat somewhere won’t have a negative attitude,” and simply dismiss the work, he says. “But we think that there’s enough momentum behind the industry today so that the positives that are obviously there can overwhelm the negatives. We have faith that the plants we grow and the products we produce have the potential to really help people with disease problems.

“Either that’s a good judgment or not, but we have faith, tremendous faith, that our capacity to help people is really there.”

But CTPharma is not pinning its future on research alone. As part of a bid to be competitive in the long-term, the company is moving to a new, 173,000-square-foot facility by Q2 2020. This new site not only will increase the canopy capacity to roughly 80,000 square feet, but will also permit the addition of an on-site commercial bakery, among other new features.

Schultz says the canopy expansion will be rolled out in phases, with the first phase doubling current capacity to 20,000 square feet. “We are the smallest … producer in Connecticut, and obviously that next facility is quite large and will allow us to do a lot of things that we can’t currently do and will provide for any future space that we may need,” he says.

And while CTPharma might be the first U.S. cannabis company to get approval for an FDA study, looking forward, the co-founders know they won’t be the last.

“[Nov. 8 was] a historic day, and we’re proud to be that company that did this, and we expect that you’re going to start to see more and more companies reaching this sort of achievement,” Ferrarese says. “But in order to do it, they’re going to have to have all the things lined up that we had: the CGMPs, the partnerships with academia, and the right professionals in place within the organization.”

Schultz puts it a little more simply (and sarcastically): “This is really easy: All it takes is two and a half years to get the enabling legislation passed so we can do research, and then another two and a half to get through the FDA.”

Brian MacIver is senior editor for Cannabis Business Times and Cannabis Dispensary magazines.

NEWS ADVISORY – INFORMATION EMBARGOED UNTIL NOV. 8th – FOR PLANNING PURPOSES ONLY

Yale School of Medicine and CTPharma Announce Groundbreaking Clinical Study with Cannabinoid Medicines on Friday, November 8th at 10:30 a.m. at Yale School of Medicine

Investigational New Drug (IND) trial will study a variety of medical conditions related to stress and pain.

Who:

·      Michael Fedele, Board Chairman, CTPharma

·      Michelle H. Seagull, Commissioner, Department of Consumer Protection

·      Tom Schultz, CEO, CTPharma

·      Rino Ferrarese, COO and Scientist, CTPharma

·      Dr. Rajita Sinha, Lead Investigator, Yale School of Medicine

What: Announcement of Groundbreaking Medical Marijuana Clinical Study

When: Friday, November 8th at 10:30 a.m.

Where: Beaumont Room, Yale School of Medicine, 133 Cedar Street, New Haven.

Yale University School of Medicine and CTPharma will conduct a Phase One clinical study of the effectiveness of various medical marijuana formulations initially aimed at alleviating stress and pain in patients. This study is the first approved by the Department of Consumer Protection’s Medical Marijuana Research Program to study stress and mental health related issues. 

The study’s initial phase is a safety and dosing study, in this case focused on pain and stress.  The study will be the first of its type on human subjects, a double-blind, randomized, placebo-controlled clinical study using medical marijuana with an FDA-approved protocol.

The clinical study will address other conditions as appropriate based on the results of Phase One. Those conditions may include Post Traumatic Stress Disorder and opioid-replacement.

Clinical Study Summary:

 Study 1:

Adult men and women aged 21-45 who are recreational marijuana users but do not meet criteria for cannabis use disorder will complete six separate inpatient laboratory sessions one week apart during which they will be assigned to receive placebo or acute doses of either 40 mg or 100 mg of CBD, and three separate combinations of CBD and low dose THC,  in a random, counter-balanced, double-blind, cross-over design over a 6-week period. Sessions will be completed one week apart to allow for an adequate washout period between sessions.

Study 2:

Adult men and women ages 21-60 with chronic pain (not fully controlled by opioid pain medication), will be recruited and randomly assigned to receive the most tolerable CBD/THC dose or placebo repeated dosing for 7 days. On day 1, 3 and 7 of the 7-day dosing, subjects will complete laboratory sessions. Subjects cannot meet criteria for cannabis use disorder or other addictive disorders.

Study outcomes/endpoints

Safety and side effects including vital signs of heart rate, systolic and diastolic blood pressure and clinical symptoms will be assessed. Laboratory chemistry will be completed on all participants. In addition, blood levels of CBD and THC and their metabolites will be assessed.

The study will measure the medications’ main pharmacokinetic characteristics, how the drugs move through the body, such as peak plasma concentration (Cmax), time to reach peak serum concentration (tmax) and serum elimination half-life (t1/2). Repeated urine sampling will allow estimating clearance and excretion functions. 

Additional outcomes will be subjective drug effects measures, stress and pain ratings, cortisol and ACTH responses and cardiovascular measures during laboratory challenge and after ingestion of study doses at repeated timepoints.

Background:

The background work for CTPharma’s current project work involving human subjects began during 2016 with Dr. Rajita Sinha at the Yale University School of Medicine. 

The Yale University School of Medicine and CTPharma filed an Investigational New Drug Application with the FDA which required substantial information about the pharmaceutical characteristics of the medication to be studied and about its use in the study.   

In 2017, Dr. Sinha at Yale University in collaboration with CTPharma received FDA approval for the Investigational New Drug protocol, “The safety of acute and repeated doses of natural medicinal marijuana products and effects on subjective and physiological responses to stress and pain.” 

In October 2019, the Yale University School of Medicine and CTPharma received approval from the Connecticut Department of Consumer Protection to proceed with the study.